

IN THE CLAIMS:

Claims 2 through 10 and 13 through 16 are cancelled herein. Claims 1, 11, 12, and 17 through 20 have been amended herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1. (Withdrawn and currently amended) A method for distinguishing between subsets of red blood cells in a sample, said method comprising:

[[contacting]] testing said sample with ~~at least a first marker reagent reactive with a first component of a red blood cell and with at least a second marker reagent reactive with a second component of a red blood cell~~ the reagent mixture of claim 17, and
determining the reactivity of said first and second ~~marker reagents~~ antibodies.

2. through 10. (Canceled).

11. (Withdrawn and currently amended) The method according to claim 1 further comprising determining the reactivity of said ~~marker reagents~~ antibodies with said red blood cells by detecting fluorescence.

12. (Currently amended) A diagnostic kit [[suitable]] for the [[differentiation]] discrimination of subsets of erythrocytes, said diagnostic kit ~~at least~~ comprising:

a first marker ~~reagent reactive~~ antibody with ~~a first component~~ hemoglobin F of a red blood cell, and

a second ~~reagent reactive~~ antibody reactive with ~~a second component~~ carbonic anhydrase B of a red blood cell, and wherein said first and second antibodies each comprise a label for detecting reactivity of the first and second antibodies with cells by flow cytometry.

13. through 16. (Canceled).

17. (Currently amended) A reagent mixture [[suitable]] for use in the [[differentiation]] discrimination of subsets of erythrocytes, said mixture comprising ~~at least~~ a first ~~marker reagent~~ antibody reactive with ~~a first component~~ hemoglobin F of a red blood cell and a second ~~marker reagent~~ antibody reactive with ~~a second component of~~ carbonic anhydrase B a red blood cell and wherein said first and second antibodies each comprise a label for detecting reactivity of the first and second antibodies with cells by flow cytometry.

18. (Withdrawn and currently amended) A method of monitoring the efficacy of an intrauterine transfusion in a fetus, said method comprising: quantifying fetal cells in a fetal blood sample by the method according to claim 1 and calculating [[the]] a percentage of a donor's red cells in the fetal circulation.

19. (Withdrawn and currently amended) A method for non-invasive prenatal testing of a fetus, said method comprising:

identifying and isolating fetal cells from a maternal blood sample utilizing the method according to claim 1, and

testing [[said]] the fetal cells.

20. (Withdrawn and currently amended) A method for distinguishing between maternal and fetal red blood cells in a blood sample, said method comprising:

contacting the blood sample with

~~a first marker reagent comprising a first binding molecule reactive with a red blood cell component predominantly associated with fetal red blood cells so as to bind fetal blood cells present in the blood sample with the first marker reagent and also~~

~~contacting the blood sample with a second marker reagent comprising a second binding molecule reactive with a red blood cell component predominantly associated with maternal red blood cells so as to bind maternal blood cells present in the blood sample with the second marker reagent,~~

~~wherein the first and second marker reagents further comprise distinct first and second labels associated with the first and second binding molecules respectively~~ the reagent mixture of claim 17, and

determining the interaction of said first and second ~~marker reagents~~ antibodies by detecting said ~~first and second~~ labels, thus distinguishing the first and second ~~marker reagents~~ antibodies from one another in the blood sample.